CT G11
Alternative Names: CT-11; CT-G11Latest Information Update: 28 May 2022
At a glance
- Originator Celltrion; Celltrion Pharmaceutical
- Developer Celltrion
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in South Korea (PO, Tablet)
- 10 Jun 2020 Celltrion completes phase I clinical trial in Cardiovascular disorders (In volunteers) in South Korea (PO) (NCT03918967)
- 19 Sep 2019 Celltrion plans to launch CT G11 for Cardiovascular disorders by 2025